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Decoding the anticancer activity of VO-clioquinol
compound: the mechanism of action and cell
death pathways in human osteosarcoma cells†
Ignacio E. León,ab Paula Dı́ez, cd Enrique J. Baran,b Susana B. Etcheverry*ab and
Manuel Fuentes *cd
Vanadium compounds were studied in recent years by considering them as a representative of a new
class of non-platinum metal anticancer drugs. However, a few challenges still remain in the discovery of
new molecular targets of these new metallodrugs. Studies on cell signaling pathways related to
vanadium compounds have scarcely been reported and so far this information is highly critical for
identifying novel targets that play a key role in the antitumor actions of vanadium complexes. This research
deals with the alterations in the intracellular signaling pathways promoted by an oxovanadium(IV) complex
with the clioquinol (5-chloro-7-iodo-8-quinolinol), VO(CQ)2, on a human osteosarcoma cell line (MG-63).
Herein are reported, for the first time, the antitumor properties of VO(CQ)2 and the relative abundance of
224 proteins (which are involved in most of the common intracellular pathways) to identify novel targets of
the studied complex. Besides, full-length human recombinant AKT1 kinase was produced by using an IVTT
system to evaluate the variation of relative tyrosin-phosphorylation levels caused by this compound. The results
of the differential protein expression levels reveal several up-regulated proteins such as CASP3, CASP6, CASP7,
CASP10, CASP11, Bcl-x, DAPK and down-regulated ones, such as PKB/AKT, DIABLO, among others. Moreover,
cell signaling pathways involved in several altered pathways related to the PKC and AP2 family have been
identified in both treatments (2.5 and 10 mM) suggesting the crucial antitumoral role of VO(CQ)2. Finally, it has
been demonstrated that this compound (10 mM, 6 h) triggers a decrease of 2-fold in in situ AKT1 expression.
Significance to metallomics
Understanding how vanadium compounds perform their role as anticancer agents is really important in the field of metallodrugs. While many mechanisms of
action for vanadium compounds are known and have been characterized (ROS generation, cell cycle arrest, tyrosine phosphatase inhibition, and ERK1 and
ERK2 activation), the present work decodes the function of many proteins (BCL10, BCL-X, CASP3, FAK and AKT1, among others) involved in the antitumor
effects of vanadium compounds against human osteosarcoma.
Introduction
Metal-based drugs have a wide spectrum of pharmacological
activities against different pathologies, including neurodegenerative
diseases, diabetes, and cancer. The capability of metallodrugs
as cancer therapeutic agents has been known since the 16th
century.1
Cisplatin, carboplatin, and oxaliplatin are the most important
and successful metal-based drugs in the clinic.2 However, a few
challenges still remain for their application (such as lack of
specificity, poor absorption, or chemoresistance, among others).
In this regard, medicinal inorganic chemistry is focused on the
development of several approaches to overcome these difficulties,
which include the design and synthesis of new metallodrugs that
have different structural features.3,4
In this regard, vanadium compounds have recently emerged
as non-platinum antitumor agents5 showing promising anticancer
effects on different types of solid tumors.6–8
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The role of vanadium in the regulation of cell signaling
pathways makes it a potential therapeutic agent, which can be
used in the treatment of several diseases. Nevertheless, the
study of activation pathways targeted by vanadium compounds
have scarcely been reported in the literature, and so far, the
data for the discovery of novel intracellular targets in cancer
have not been completely examined. In this regard Tiago and
collaborators described the importance of MAPK and PI-3K-Ras-Erk
pathways on the anti-mineralogenic properties of vanadate in a fish
chondrocyte cell line.9,10
Our recently reported results demonstrated that vanadium
compounds increase the cytotoxicity levels, induce cell cycle
arrest and apoptosis in human osteosarcoma cells involving
AKT and FAK cell signaling pathways.11,12 In this context, there
is great interest in deciphering the targets of novel vanadium
compounds affecting the cell signaling pathways related to the
anticancer activity.
In the last few years, the use of protein microarrays has
appeared to be a high-throughput method to provide a suitable
tool for the discovery of new molecular drug targets.13 Despite
the progress in the protein microarray area, a few challenges
still remain. Hence, in order to overcome these challenges, a
complementary method named NAPPA (Nucleic Acid Program-
mable Protein Arrays) has been developed.14 Full-length human
recombinant proteins expressed in situ have been successfully
applied for the study of protein–protein and protein–drug
interactions.15
Here, it is proposed to identify novel targets of vanadium by
using both protein array approaches (relative abundance based
antibody arrays and in situ protein arrays). This research deals
with the effects of intracellular signaling of an oxovanadium(IV)
complex with the clioquinol (5-chloro-7-iodo-8-quinolinol),
VO(CQ)2, on a human osteosarcoma cell line (MG-63). We have
investigated and reported for the first time the effect of VO(CQ)2
on the relative abundance protein patterns of 224 proteins
involved in most common intracellular signaling pathways and
the relationship with the mechanism of cell death. In addition,
full-length human recombinant AKT1 kinase has been produced
in situ using rabbit reticulocyte lysate (RRL) in vitro protein
expression systems; then, the protein expression levels and the




Tissue culture materials were purchased from Corning (Princeton,
NJ, USA), Panorama Cell Signalling Kit and RPMI 1640 (Sigma
Chemical Co. St Louis, MO, USA), trypsin and fetal bovine serum
(FBS) from Gibco (Gaithersburg, MD, USA), RC DC Protein Assay
Kit from Bio-Rad, Protein-G-agarose beads, Cy3 and Cy5
from (GE Healthcare, CA, USA, Purefieldt Plasmid Miniprep
System from (Promega, Wisconsin, USA)), mouse antibody anti-
phosphotyrosine from (Millipore, MA, USA), rabbit polyclonal
anti-GST from GE Healthcare, monoclonal anti-GST from Cell
Signaling, anti-mouse-HRP from (Jackson ImmunoResearch
Laboratories, West Grove, PA).
The MG-63 cell line was purchased from ATCC.
Methods
Synthesis and identification of VO(CQ)2
VO(CQ)2 was synthesized according to previously reported results.
16
Briefly, clioquinol (0.61 g) was dissolved in 150 mL of warm
ethanol. To this solution, 0.35 g of VOSO45H2O mixed in 10 mL
of hot ethanol was added dropwise. The solution became dark and
the complex precipitated after stirring for a short while. After
digestion for a short while over a water bath, it was filtered, washed
with absolute ethanol and dried for 3 days at 60 1C.
Anal. calc. for C18H8N2O3Cl2I2V C 31.91; H 1.18; N 4.14; V
7.54; exp. C 31.80; H 1.27; N 4.26; V 7.66. The identification of
the complex was done by FTIR.
Preparation of VO(CQ)2 solutions
Fresh stock solutions of the complex were prepared in DMSO at
20 mM and diluted according to the concentrations indicated
in the legends of the figures. We used 0.5% as the maximum
DMSO concentration in order to avoid the toxic effects of this
solvent on the cells.
Stability of the complex in solution
To test the stability of the compound under the different
experimental conditions used in this work, we analyzed the
UV-visible spectra of different solutions of the complex. 20 mM
solutions of complex in DMSO and 0.01 mM of complex in
medium RPMI (pH = 7.4) were prepared. The electronic spectra
were recorded at times ranging from 0 to 6 h at room temperature
and at 37 1C. The rate of decomposition of the complex was
spectrophotometrically measured.
Cell culture conditions
MG-63 cells were grown in RPMI 1640 medium containing 10%
FBS, 100 U mL1 penicillin and 100 mg ml1 streptomycin
at 37 1C under a 5% CO2 atmosphere. Cells were seeded in a
175 cm2 flask and when 70–80% confluence was reached, the
cells were subcultured using 4 mL of trypsin per 175 cm2 flask.
For experiments, cells were grown in a 75 cm2 flask for 24 h at
37 1C. Then, the monolayer was incubated with different
concentrations (25 and 100 mM) of the complex.
Measurement of the exposure of phosphatidylserine (PS) by
annexin V-FITC/PI staining
Cells in early and late stages of apoptosis were detected by
annexin V-FITC and propidium iodide (PI) staining. Thus, cells
were washed with PBS and adjusted to a concentration of
1  106 cell per mL in 1 mL binding buffer (0.01 M HEPES,
pH 7.4; 0.14 M NaCl; 2.5 mM CaCl2). To 100 mL of cell
suspension, 2.5 mL of annexin V-FITC were added and incubated
for 15 min at room temperature. Finally, 2 mL PI (250 mg mL1)
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cytometer CyAnt ADP (Beckman Coulter, USA) and Summit v4.3
software.
Mitochondrial membrane potential (MMP)
The cells cultured in 24-well plates were washed with PBS and
incubated with 5 mg ml1 rhodamine 123 for 30 min at 37 1C.
After further washing, the cells were incubated with DMEM for
30 min. The changes in MMP were analyzed using a flow
cytometer CyAnt ADP (Beckman Coulter, USA) and Summit
v4.3 software.
Subcellular protein fractionation and dye-labeling
Cytoplasmic proteins were isolated by using a sub-fractionation
protocol. The cells were harvested and washed three times with
PBS. Then, three portions of lysis buffer were added (5 mM
HEPES, 10 mM MgCl2, 140 mM NaCl, 0.1% (v/v) Tween 20 at
pH 8.0, 1% (v/v) protease inhibitor mix). Briefly, lysed cells were
centrifuged for 15 min at 15 000g at 4 1C. After that, the
supernatant was collected and 10% (w/v) octyl-b-D-glucopyranoside
was added followed by sonication (3 times with 3 second bursts).
Samples were preserved on ice for 30 min and then centrifuged,
yielding the cytoplasmic fraction. Immediately after IgG depletion
(by using protein-G-agarose beads), purified proteins were quanti-
fied by Lowry assay following the manufacturer’s instructions. Then,
cytoplasmic proteins were conjugated with Cy3 or Cy5 at a dye/
protein ratio 42 following the manufacturer’s recommendations.
Antibody microarray assays
The functional proteomic analysis was performed by using the
Panorama Cell Signaling Kit following the manufacturer’s
instructions. The antibody microarray consists of 224 human
monoclonal antibodies targeting proteins involved in intracellular
signaling pathways, spotted in duplicate onto a nitrocellulose-
coated slide. Equal amounts of fluorescently labeled proteins of
osteosarcoma cells from basal condition (control) and from
treatments with vanadium complex (each with a different dye)
were incubated with the microarray slide at RT for 1 h on an
orbital shaker. For optimal and robust characterization of the
differences in relative protein abundance under all the tested
conditions, and according to the manufacturer, only proteins that
presented a Cy5/Cy3 ratio Z2 (up) and a ratio Cy5/Cy3 r0.5
(down) have been taken into consideration for the identification
of altered intracellular pathways.
Antibody microarray data analysis
Microarrays were scanned using Scanner GenePix 4000B (Axon,
USA) using Cy3 and Cy5 settings. The images were analyzed
using GenePix Pro 4.0 software (Axon, USA).
Firstly, background correction for each spot was locally
obtained by applying standardized settings of GenePix software.
Then, the mean value of the set of negative control spots in each
fluorescence channel was subtracted from the individual spot
values. Before statistical analysis (MultiExperiment Viewer (MeV)
clustering and Significance Analysis of Microarrays (SAM)), the
raw intensity data for each slide were normalized by reference
(housekeeping) proteins. The fluorescence intensity obtained for
each protein in the array was divided by the fluorescence
intensity obtained for a highly expressed reference protein. We
performed a Z-score estimation for the housekeeping proteins
in the array and selected those with a high value (42) for the
normalization.
In all cases, the mean of the protein replicates was calculated
to obtain a single value per protein/assay.17
Functional annotation of down-/up-regulated expressed
proteins
Altered-expression proteins were selected by computing a rela-
tion between each condition (control vs. vanadium treatment)
after applying the normalization strategy described above.
Significance was assigned to proteins whose ratio was greater
than or equal to 2.0 or less than or equal to 0.5.
The functional annotation of the selected proteins was
analyzed using the GeneCodis tool including gene ontology
(GO) annotations and Circos software.
Self-assembled protein arrays in the multi-well format
(NAPPA-ELISA)
The list of candidate kinases selected for targeted screening
was built on the basis of the Panorama Cell Signaling Kit
results. The cDNA (encoding corresponding full-length human
proteins) employed in the NAPPA-ELISA is AKT1.
cDNA preparation
Escherichia coli bearing a total of 2 sequence-verified full-length
human genes in pANT7_cGST were obtained from the Center
for Personalized Diagnostics at the Arizona State University and
are publicly available (www.dnasu.org). Bacteria were grown for
24 h at 37 1C in 100 mL of Luria–Bertani medium supplemented
with ampicillin for cGST clones. The cells were pelleted and their
plasmid DNA was purified using the Purefieldt Plasmid Miniprep
System according to the manufacturer’s instructions.
In situ protein expression
The in vitro transcription and translation steps were performed
as previously described by Manzano-Román et al.18 The
transcription/translation lysate mix was added into the tubes.
The tubes were incubated for 1.5 h at 30 1C for protein
expression and capture using an anti-GST polyclonal rabbit
antibody.
NAPPA-ELISA assay
A GST fused to the AKT1 full-length human gene was expressed
in vitro using the rabbit reticulocyte lysate, as previously
described.18,19
The FAK and AKT1 proteins were then applied onto anti-GST-
coated 96-well plates. The plates were washed with 0.02%
PBS-Tween and blocked with PBS–Tween with 5% milk overnight
at 4 1C. After washing, the plate was incubated with the 1 : 1000 (v/v)
diluted anti-GST and anti-phosphotyrosine mouse antibodies. The
presence of the specific protein was detected by incubation with the
HRP-linked anti-mouse secondary antibody diluted 1 : 1000 (v/v) in


















A user on 25 M
ay 2021
894 | Metallomics, 2017, 9, 891--901 This journal is©The Royal Society of Chemistry 2017
the reaction was stopped. The 450 nm signals were read and the
absorbances were subjected to t-test analysis to determine the
significance of any variation in the antibody levels between
the samples.
Results and discussion
Synthesis, characterization and stability studies of VO(CQ)2
VO(CQ)2 (Fig. 1A) was synthesized as previously described
by Gonzáles Baró and Baran16 (see the Experimental section).
The final product was characterized by FTIR, with the main
vibrations being fully comparable with the organic moiety,
allowing an accurate identification.
Since DMSO has been used as a co-solvent in biological
systems, we explored the stability of the VO(CQ)2 complex in
DMSO and RPMI solutions (pH = 7.4) using UV-vis spectroscopy.
In the electronic absorption spectrum of VO(CQ)2 (0.02 M
in DMSO solution) one d–d transition was observed at 782
(e = 51 M1 cm1). Upon monitoring this solution with time
(0.25, 0.5, 1, 2, 3 and 6 h), no changes were observed in the
UV-vis signals, and the integrity of the complex in DMSO was
intact within the time-frame of the biological experiments (see
Fig. 1B). Besides, in the electronic absorption spectrum of
VO(CQ)2 (0.00001 M in RPMI solution) one charge transfer band
was observed at 295 nm (e = 27 000 M1 cm1) and upon
monitoring this solution no changes were observed.
These results suggest that the compound does not undergo
oxidation and is stable over time.
Cytotoxic activity and apoptosis induced by VO(CQ)2 in human
osteosarcoma MG-63 cells
VO(CQ)2 caused a concentration-dependent inhibition of
cell viability in human osteosarcoma MG-63 cells. The anti-
proliferative action of the complex is much stronger as a
consequence of a cooperative/synergy effect of the free clioquinol
and the vanadyl cation, demonstrating the improvement of the
antitumoral action through the complexation of the ligand with
vanadyl(IV). This is also evident from the IC50 values in MG-63
cells: VO(CQ)2 ca. 7 mM while for clioquinol this value is 59 mM
and for VO(+2) the IC50 value is 4100 mM (see Fig. 2A).
Mitochondria are one of the most important organelles that
can regulate cellular apoptosis.20 To elucidate whether VO(CQ)2
induces cytotoxicity in human osteoblasts by alterations
of mitochondrial functions, we evaluated the Mitochondria
Membrane Potential (MMP) in MG-63 cells under control
conditions and in the presence of different concentrations
(1 and 2.5 mM) of the compound.
After 24 h of incubation, as can be seen in Fig. 2B and Fig. S1
(ESI†), the fluorescence intensity of rhodamine 123 shifted to
the left, indicating the dissipation of MMP as the dose of the
complex increased. The fractions of cells that displayed low
fluorescence intensities were 20, 27 and 47% for 0, 1 and
2.5 mM of VO(CQ)2, respectively. The results suggest that the
effect of the compound on MMP is, at least partly, one of the
principal mechanisms of action involved in the antitumoral
actions of VO(CQ)2. In order to confirm the MMP obtained
results and to obtain deeper insight into the apoptosis induced
by VO(CQ)2, we tested four concentrations of the complex
(1, 2.5, 5, and 10) and two incubation times (6 and 24 h).
Table 1, Fig. 2(C and D) and 3 display the quantification of the
early and late stages of apoptosis obtained by flow cytometry in
MG-63 cells. As can be seen, after 6 h of incubation the control
cultures showed 0.47% of early apoptotic cells (annexin V
positive) and 2.5% of late apoptotic cells (annexin V positive/
propidium iodide (PI) positive). These results changed with the
treatment showing an increase in the early apoptotic cellular
fraction (8.1%) and the late apoptotic cells (9%).
After 24 h of incubation, VO(CQ)2 resulted in approximately 6%
of early apoptotic cells at 5 mM (vs. 1% of basal conditions) whilst
this compound increased 17, 27 and 42% cells of late apoptotic
features at 1, 2.5 and 5 mM, respectively (vs. 6% of control).
These results are in accordance with the viability assays,
confirming that the deleterious action of VO(CQ)2 is dependent
on its concentration and time in the MG-63 cell line.
On the other hand, the results indicate that VO(CQ)2 has
greater antitumor actions in human osteosarcoma cells than in
non-transformed mouse fibroblasts (L929).
Fig. 1 Vanadium complex structure. (A) Chemical proposed structure of the oxovanadium(IV)–clioquinol complex; (B) UV-vis spectra of VO(CQ)2
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As a whole, these results demonstrate that VO(CQ)2 is a
potentially very good candidate for further evaluation of its
molecular targets since it is less toxic to the normal phenotype cells
(L929) and is highly deleterious for the human osteosarcoma cells.
Decrypting altered cell signaling pathways by VO(CQ)2
treatment in human osteosarcoma MG-63 cells
Based on the biological results previously described, and in
order to identify the relative differences in protein patterns, a
time and concentration course treatment in MG-63 cells with
VO(CQ)2 was achieved with abundance-based protein arrays
as described in the Experimental section. According to reported
data about VO(CQ)2, several comparison studies were performed
with soluble proteins (i.e., cytoplasmatic, nuclear, among others)
from control conditions and different treatments with VO(CQ)2
(2.5 mM 6 h and 10 mM 6 h). This experimental proposal allows
decoding of altered cell signaling pathways by the effect of
VO(CQ)2 by studying global differential protein expression profiles
and the potential correlation with the anticancer activity of this
metallodrug in human osteosarcoma cells.
Table 2 shows that after 6 h and 2.5 mM VO(CQ)2 treatment
(condition 1), forty-nine up-regulated proteins and eleven down-
regulated proteins were detected (see S3, ESI†), while for condition 2,
the vanadium compound only up-regulated twenty proteins
(see S4, ESI†). Taken together, these results demonstrate the
presence of significant differences in protein expression profiles
as a consequence of the expected targeted effect of this metallo-
drug in several intracellular signaling pathways. The main proteins
identified within differential expression profiles are grouped and
discussed below in canonical signaling pathways: (1) apoptosis,
(2) cell cycle, (3) cell stress and (4) signalling transduction.
Fig. 4 shows a summary of altered relative protein abundance
detected in each treatment with VO(CQ)2. As it can be seen in the
Fig. 2 Effect of VO(CQ)2 on cell viability and apoptosis (B–D). (A) Cell viability test: MG-63 cells were treated with VO(CQ)2 at 0–100 mM (1, 2.5, 5, 10, 25,
50 and 100 mM) at 37 1C for 24 h. (B) Mitochondrial membrane potential (MMP) assay: MG-63 cells were treated with VO(CQ)2 at 0, 1 and 2.5 mM at 37 1C
for 24 h. (C and D) Apoptosis studies: MG-63 cells were treated with VO(CQ)2 at 0, 1, 2.5 and 5 mM at 37 1C for 6 and 24 h. The cell viability test was
assessed by MTT and the apoptosis studies by flow cytometry using rhodamine 123 (B) and annexin V–fluorescein isothiocyanate (FITC)/propidium iodide
(PI) staining (C and D).
Table 1 Percentage of apoptotic cells treated with VO(CQ)2. The results
are expressed as the mean  the standard error of the mean of three
independent experiments (n = 9)
VO(CQ)2
Annexin V+/PI Annexin V+/PI+
6 h 12 h 6 h 12 h
0 mM 0.47 1.13 2.50 6.50
1 mM ND 1.25 ND 17.50*
2.5 mM 0.40 0.97 3.25 26.80*
5 mM 1.20 6.30* 6.15* 42.00*
10 mM 8.10* ND 9.00* ND
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Fig. 4A (2.5 mM VO(CQ)2), the complex induced the increase of
relative levels of antiapoptotic proteins (Bcl-x) and pro-apoptotic
proteins (Bcl-10, CASP6, CASP7, CASP10 and CASP11). Besides,
this compound shows an effect on up-regulation of the level of
phosphatidylserine receptor (early apoptosis biomarker) and on
the DAP-kinase levels (a late apoptosis biomarker) in concordance
with previous results described above. Moreover, low abundance
protein levels of active CASP3, PAR4 and SMAC/DIABLO, all
proteins with a pro-apoptotic function, have been reported. The
down-regulation levels of these important proteins involved in the
apoptosis process may be an alternative for tumor escape and
chemoresistance. This down-regulation may be mediated by Bcl-x,
which acts as an anti-apoptotic protein by preventing the release
of mitochondrial contents (cytochrome c). These actions lead to
caspase activation and induce apoptosis.
Additionally, the Cy5/Cy3 ratio of Bcl-x is higher for condi-
tion 1 than condition 2 (2.89 vs. 2.18). This effect of the complex
concentration may explain the up-regulation level of active
CASP3 for condition 2 (see Fig. 4B) and its cross-regulation
with Bcl-x. This fact has been previously demonstrated by many
scientific reports showing a close relationship between Bcl-x
and pro-apoptosis proteins.21,22
Moreover, VO(CQ)2 seems to induce the up-regulation of
several proteins involved in the cell cycle regulation, such as
c-Myc, E2F1, cyclin D3, p21Waf-1, SMAD4, Ap-1/cjun, ATF2,
HADC4, and PCAF, among others, suggesting the key role of
these transcription factors in cell cycle progress and apoptosis.
Besides, for condition 1, several cytoskeleton-related proteins
(cytokeratin family, myosin. . .) were detected as up-regulated.
On the other hand, PKB/AKT pathways are down-regulated
suggesting the important role of these pathways in the anti-
cancer activity of VO(CQ)2. In this way, several research reports
showed the relevant relationship between blocked AKT pathways
and apoptosis inhibition.23,24 In addition, the interaction between
vanadium compounds with anti-diabetic actions and the AKT cell
signaling pathway has been reported.25,26
Other important findings for condition 2 are related to
HSP90 and Nedd 8, which appeared to be up-regulated. HSP90
and Nedd 8 stabilize a number of proteins required for tumor
growth, which are involved in the cell stress response suggesting
that the osteosarcoma tumor may use these proteins for an
alternative way toward drug chemotherapy.
Ten up-regulated proteins were identified to be common
between conditions 1 and 2 (Fig. 4). In both cases, there was
an enrichment in FAK (Tyr577), HSP90, PKCb, PKCg, AP2beta,
AP2gamma, AP2alpha, DOPA decarboxylase and glutamate
receptor NMDAR 2a.
The levels of PKCb and PKCg are higher for condition 2 than
condition 1, suggesting the importance of these kinases in the
anticancer activity of VO(CQ)2 (see Fig. 4). In this regard, Mehdi
and co-workers established that PKC protein is required to
stimulate PKB/AKT phosphorylation in response to the anti-
diabetic actions of vanadium(IV) oxo-bis(maltolate) (BMOV) in
HepG2 cells.27 In the same way, relative levels of PKC were
up-regulated, which could be linked to restoring the proteasome
activity and abrogating osteosarcoma cellular differentiation.28
Fig. 3 Apoptosis studies after 6 h (A) and 24 h (B) of incubation. The plots are representative of three independent experiments. The numbers in the
Q1-LR and Q1-UR quadrants indicate the proportions of cells that are annexin V positive/PI negative and annexin V positive/PI positive, respectively.
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For focal adhesion kinase (FAK), the results showed that the
compound up-regulated the site of phosphorylation Tyr577
(see Data S3 and S4, ESI†). The Tyr577 site of tyrosine phosphor-
ylation is one of the most important regulatory sites of FAK.
In this way, Tyr577 produce FAK bis-phosphorylated at Tyr576
and Tyr577.29 The level of Tyr577 is higher for condition 1 than
for condition 2 (see Data S3 and S4, ESI†), suggesting the
importance of this site of phosphorylation in the response of
tumor against chemotherapeutic drug actions.
FAK, also known as protein kinase 2 (PTK2), is a protein
tyrosine kinase that controls motility, proliferation, and survival
in several types of solid tumors. Interestingly, FAK is well-
characterized as over-expressed and activated in several
advanced-stage solid cancers and it promotes tumor progression
and metastasis.30 Consequently, FAK has become a potential
prognostic marker and antitumor molecular target.31 In addition,
FAK and EGFR also induce cooperative signals that suppress
apoptosis and enhance cell survival in breast cancer cells through
activation of the ERK and AKT pathways.32
On the other hand, the AP2 family (alpha, beta, and gamma)
was up-regulated in both treatments (conditions 1 and 2).
These results suggest that this family of transcription factors
may be involved in the anticancer activity of VO(CQ)2. In this
context, several scientific reports showed a direct correlation in
the over-expression of the AP2 family and the inhibition of
cancer cell growth in different types of cancers, such as liver,
breast, and colon.33–35 Our results showed the up-regulation of
AP2 family proteins and the universal cell cycle inhibitor
(p21WAF1), suggesting a strong correlation between both proteins.
Similar results were described by Zeng et al. for HepG2 human
hepatoblastoma and SW480 human colon adenocarcinoma.35
In order to get a deeper insight into the biological context,
all the up/down differentially expressed proteins in different
treatments were subjected to functional characterization using
the bioinformatics software DAVID 6.7 (S5–S7, ESI†).
Identification of potential novel targets by determination
of differential expression profiles
We set out to characterize the potential molecular targets
and the related pathways involved in the anticancer actions of
VO(CQ)2 against human osteosarcoma cells. To perform cell
signaling pathway analysis, the down- and up-regulated proteins
identified in each group of treatment have been included in the
analysis. In Fig. 5, the PKC family (PKCb, PKCg), FAK (Tyr577),
HSP90, AP2 family (beta, gamma, and alpha) and MAPK1 were
common in all the treatments suggesting the significant role of
these proteins associated with the anticancer activity of VO(CQ)2.
In addition, as it can be seen in Fig. 6A, the role of these
proteins in cancer cell signaling pathways confirmed the com-
plexity interaction network of the different proteins with differ-
ential functions related to the anticancer effects of VO(CQ)2.
Moreover, PKC activates PI3K and PKB/AKT increasing gene
transcription levels involved in evading apoptosis, proliferation
and sustained angiogenesis, such as Bcl-xL. On the other hand,
Fig. 4 Main altered proteins detected in each group of treatment. (A) Values of the Cy5/Cy3 ratio for the treatment with 2.5 mM of VO(CQ)2. (B) Values of
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CASP3 and DAPK (related to the inhibition of the ERK pathway)
convey to apoptosis. Moreover, Fig. 6B shows the important
role of CASP10 that activates CASP3, CASP6, and CASP7 that
exert an inhibition on PARP, lamin, fodrin, and actin. These
proteins control the regulation of actin cytoskeleton through
activation of the actin polymerization and actin filament turnover;
therefore, the loss of integrity of the cell membrane and the
membrane bleb formation trigger programmed cell death.
Besides, PKB/AKT phosphorylate Bad and inhibit the Bcl2
and Bcl-XL (anti-apoptotic functions) whilst cathepsin exerts a
direct inhibition of Bcl-xL functions.
Functional validation assay by IVTT in situ protein expression
of targeted VO(CQ)2 kinases
The effect of VO(CQ)2 on kinases has been validated by func-
tional screening using IVTT recombinant human kinase assays.
The human full-length recombinant AKT1 kinase (GST-tagged
in COOH terminus) was expressed by using a cell-free protein
IVTT expression system. Hence, AKT1 kinase was selected
based on Panorama array results and due to its promising
therapeutic applications. In both cases, the full-length IVTT
expressed recombinant protein was detected by anti-GST mouse
antibody. The results show that the presence of VO(CQ)2 does not
affect the IVTT protein expression.
In order to study the pattern of tyrosine phosphorylation
sites induced by VO(CQ)2 in AKT1 kinase, we evaluated the
phospho-tyrosine/GST signal ratio.
The values for the Tyr/GST ratio are 0.38 (control), 0.24* (2.5 mM)
and 0.19* (10 mM), respectively. These results showed that VO(CQ)2
generated a reduction in the Tyr/GST ratio suggesting that the
complex diminished the level of tyrosine phosphorylation of AKT
kinase with statistical significance (*p o 0.01). These results
Fig. 5 Circos representation. The outer circos data track shows the differential protein pathways in each group of the study. The AP2, PKC, FAK, and
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Fig. 6 Cancer cell signaling pathways induced by VO(CQ)2. The cell signaling pathway graphic shows the role of different proteins down-/up-regulated
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correlate with the data obtained in the antibody array study, in
which we could establish that the complex down-regulated the
PKB/AKT pathways signifying the important role of this pathway
in the anticancer activity of VO(CQ)2.
Our results show that VO(CQ)2 selectively inhibits the phos-
phorylation of AKT1 kinase, whereby the complex may act as a
down-regulator of AKT1 cell signaling (see Fig. 6B).
Conclusion
New oxovanadium complexes with potential antitumor properties
currently require more intensive exploration since information
obtained from the in vitro studies may allow vanadium drugs
to enter the preclinical in vivo phase. On this basis, we have
thoroughly investigated the novel targets of the oxovanadium(IV)–
clioquinol compound by using antibody arrays platforms and
in situ protein arrays.
We have investigated and reported herein for the first time
the effects of VO(CQ)2 on intracellular signaling in a human
osteosarcoma cell line (MG-63) and the relationship with the
pro-apoptotic activity of this compound. Besides, we have
studied the protein expression levels and the inhibition of
tyrosine phosphorylation induced by VO(CQ)2. The results showed
that the compound up-regulated proteins (CASP3, CASP6, CASP7,
CASP10, Bcl-10, Bcl-x) and caused the down-regulation of impor-
tant proteins, such as PKB/AKT, PARP, DIABLO, among others
(see Fig. 7). Besides, the PKC family, FAK, HSP90, AP2 family
(beta, gamma, and alpha) and MAPK1 were found to be
commonly expressed in both treatments suggesting the key
role of these proteins in the antitumor activity of VO(CQ)2.
On the other hand, the compound reduced the Tyr/GST ratio
of AKT1, demonstrating the importance of inactivation of the
AKT pathway in the antitumor effects of this vanadium compound.
Taken together, these results indicate that VO(CQ)2 is a
promising candidate with potential anticancer activity providing
new insights into the design of vanadium compounds as
potential anticancer agents.
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